DAVID HENDERSON
VICE PRESIDENT - COMMERCIAL
25 years experience in technology marketing, development and licencing, and angel and venture capital investment
- Member of 2 venture capital/seed investment committees with over $170million under management, and 3 startup company boards.
- Former Managing Director of UniQuest Pty Ltd which, during his tenure, lodged 250 patents, negotiated over 150 licences, and established 70 startups including 46 life sciences companies that have raised $400 million.
- Personally managed the commercial arrangements for the University of Queensland’s cervical cancer vaccine Gardasil
- Managed startup companies in the USA and Australia, completed an MBA at Harvard, then worked for McKinsey and Booz Allen
Novoviah is dedicated to pioneering sensitive clinical tests for antigen-specific T cells, supporting clinical trials for drug developers and researchers. Established in 2020, Novoviah specialised in developing a cutting-edge testing platform for clinical trials and aspires to expand its usage into healthcare settings in the future. With a focus on enhancing pharmaceutical programs, Novoviah is committed to developing customised and highly precise blood tests for a variety of medical conditions associated with antigen-specific T cells.
Level 6, 200 Adelaide Street,
Brisbane City, QLD 4000,
Australia
Phone +61418745404
Email: [email protected]